BR112017003622A2 - ?composição imunogênica, método para a preparação de uma composição imunogênica, sistema adjuvante, método para a preparação do sistema adjuvante, composição farmacêutica e vacina? - Google Patents

?composição imunogênica, método para a preparação de uma composição imunogênica, sistema adjuvante, método para a preparação do sistema adjuvante, composição farmacêutica e vacina?

Info

Publication number
BR112017003622A2
BR112017003622A2 BR112017003622A BR112017003622A BR112017003622A2 BR 112017003622 A2 BR112017003622 A2 BR 112017003622A2 BR 112017003622 A BR112017003622 A BR 112017003622A BR 112017003622 A BR112017003622 A BR 112017003622A BR 112017003622 A2 BR112017003622 A2 BR 112017003622A2
Authority
BR
Brazil
Prior art keywords
preparing
adjuvant system
immunogenic composition
adjuvant
vaccine
Prior art date
Application number
BR112017003622A
Other languages
English (en)
Inventor
Fichera Epifanio
Gupta Gaurav
Glueck Reinhard
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of BR112017003622A2 publication Critical patent/BR112017003622A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente invenção refere-se à preparação de um sistema adjuvante para se conseguir e alcançar um nível de imunoresposta humoral e celular contra o antígeno de interesse. a presente invenção proporciona um sistema adjuvante compreendendo um virossoma de influenza imunoestimulante reconstituído (irivs) e imunopotenciadores. a invenção ilustra que um antígeno é adsorvido ou incorporado no irivs e é adicionalmente formulado com um adjuvante lipofílico tal como mpl ou um adjuvante lipídeo de glucopiranosila (o análogo sintetizado de mpl).
BR112017003622A 2014-09-02 2015-09-01 ?composição imunogênica, método para a preparação de uma composição imunogênica, sistema adjuvante, método para a preparação do sistema adjuvante, composição farmacêutica e vacina? BR112017003622A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2794MU2014 2014-09-02
PCT/IN2015/000340 WO2016035096A2 (en) 2014-09-02 2015-09-01 Synergistic compositions of immunostimulating reconstituted influenza virosomes with immunopotentiators and vaccines containing them

Publications (1)

Publication Number Publication Date
BR112017003622A2 true BR112017003622A2 (pt) 2017-12-05

Family

ID=54848870

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017003622A BR112017003622A2 (pt) 2014-09-02 2015-09-01 ?composição imunogênica, método para a preparação de uma composição imunogênica, sistema adjuvante, método para a preparação do sistema adjuvante, composição farmacêutica e vacina?

Country Status (10)

Country Link
US (1) US20170296638A1 (pt)
EP (1) EP3188756A2 (pt)
CN (1) CN109069618A (pt)
AR (1) AR101738A1 (pt)
AU (1) AU2015310518A1 (pt)
BR (1) BR112017003622A2 (pt)
CA (1) CA2958219A1 (pt)
MX (1) MX2017002658A (pt)
TW (1) TW201620926A (pt)
WO (1) WO2016035096A2 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU655823B2 (en) 1991-05-08 1995-01-12 Crucell Switzerland Ag Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
SI2068918T1 (sl) * 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala

Also Published As

Publication number Publication date
CN109069618A (zh) 2018-12-21
AU2015310518A1 (en) 2017-03-09
MX2017002658A (es) 2017-09-19
AR101738A1 (es) 2017-01-11
TW201620926A (zh) 2016-06-16
US20170296638A1 (en) 2017-10-19
WO2016035096A2 (en) 2016-03-10
EP3188756A2 (en) 2017-07-12
CA2958219A1 (en) 2016-03-10
WO2016035096A3 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
BR112016024644A2 (pt) vacinas de ácido nucleico
CO6331297A2 (es) Composiciones adyuvantes novedosas
EP3916091A3 (en) Dry powder composition comprising long-chain rna
TR201908003T4 (tr) TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
PH12016500456A1 (en) Oil-based adjuvant
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
EP3556353A3 (en) Lipid nanoparticle vaccine adjuvants and antigen delivery systems
CL2016003048A1 (es) Analogos de panonina minimas sintesis y uso de los mismos.
BR112016006326A2 (pt) formulação seca de uma vacina, uso de uma formulação seca, método para fabricação de uma formulação seca, e, vacina
MX2017012220A (es) Composiciones adyuvantes y metodos relacionados.
PE20151588A1 (es) Vacuna contra el virus del dengue
MX2022002106A (es) Formulaciones de vacuna de vial unico.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
BR112018006567A2 (pt) vacinas de partículas semelhantes a vírus (vlp) do parvovirus canino (cpv) e seus usos
AU2011280259A8 (en) Influenza vaccine
BR112017005821A2 (pt) formulação aquosa, método para a preparação de uma formulação aquosa, conjunto, método para a preparação de uma composição farmacêutica, composição farmacêutica e método para quimicamente estabilizar uma formulação aquosa
BR112017012220A2 (pt) processos para preparar uma composição de antígeno e uma vacina, composição de antígeno, vacina, usos de uma composição de antígeno e de uma vacina, e, método para prevenção ou redução de infecção por um vírus em suíno e sinais associados à doença.
CO2017007057A2 (es) Vacuna contra la fiebre aftosa
BR112015021523A2 (pt) composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa
BR112012030619A2 (pt) concentração de antígenos de vacina influenza sem liofilização.
BR112014020025A8 (pt) Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
BR112016001686A2 (pt) Vacina, método para a preparação de uma vacina, composição, e, uso de uma composição

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired